The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Hi DSSLOAN,
I'm sure Selftrade will be sending out some comms to all shareholders soon. In fact, just today, Halifax sent out one. They have stated that if the company de-lists, any shares held in an ISA will automatically be transferred to your Sharedealing account. However, they have also stated that they are unable to facilitate trades on the Matched Bargain Settlement Facility that our directors are intending to setup and maintain. Therefore, your shares will need to be transferred or withdrawn to certificate if you want to trade them on this platform post de-list
Hi DSS,
Yes AJBELL sent similar comms as they do not allow delisted shares in their ISA’s or SIPP’s.
I believe the last line you are referring to is mentioning the option of transferring your holding into certificate form. This will be paper based, under your name and represent the amount of shares that you hold.
The other option is to transfer to another broker (eg. A share dealing account), however, what I am cautious about is if the transfer is still in process at the point of delisting (if it happens). Not sure what would happen then and transfers do take a long time (1 month is very tight IMHO).
Perhaps someone else can shed some light on this situation?
HAHA yeah nice one SirBoy! Love it!
Have some admin questions, which I was wondering if anyone could help with please?
1. the comms mentions that votes can be casted via signalshare. However, Signalshare require your Investor Code in order to register. Where can we get this code if we haven't transferred our holding out to certificate?
2. the comms also states: If you do not wish to consent to website publication and would prefer to continue to receive hard copies of future documents and information through the post, you must complete the enclosed electronic communications preference form. As far as I could see, no form was enclosed?
Thanks for sharing. Interesting...
But was anyone able to get a quote today?
Morning Sareumites!
Hope all are well. Not sure if this has been posted already, but noticed that TYK2 has been directly called out in The Guardian:
https://amp.theguardian.com/science/2020/nov/01/covids-effect-on-health-blamed-on-tiny-genetic-variations
“Research is also focusing on a gene known as TYK2. Some variants of this gene are involved in triggering some auto-immune diseases such as rheumatoid arthritis (RA) and also seems to be involved in causing severe Covid. A drug developed to treat RA, baricitinib, has a genetic common denominator with Covid and this has led to it being used in clinical trails against the virus. Last month the pharmaceutical company Eli Lilly announced that early results showed the drug helped Covid patients recover.“
GLA! Exciting times!
FINAL results out
Been offered 1.1266 to sell a million on HF. Not a bad start.
STRONG HOLD
PART 2:
Soooo...Lilly have been studying baricitinib in controlled trials in order to better characterize its potential benefits and understand the safety of its use as a COVID-19 treatment. As per above, they seem to be making good progress and the world has definitely taken note! However, as Stoney says, the U.S. prescribing information for the approved use of baricitinib for RA includes boxed warnings regarding the use of baricitinib, including warnings about risk for developing blood clots and serious infections....
You can bet your bottom dollar that Lilly’s competitors are following the good results exhibited from their ongoing trials. Let’s just hope that with the US patent in place, one of them (at least!) now moves to snap up Sareum’s “potentially best in class” TYK2/JAK1 inhibitor which has shown “compelling results”.
There is notable interest in the pharmaceutical industry for novel molecules that can selectively target TYK2 and JAK1, and particularly for those that can avoid the potentially dangerous side-effects caused by targeting JAK2 or JAK3. Don’t forget, both of SAR’s primary, wholly owned molecules (SDC-1801/SDC-1802) have demonstrated high selectivity for TYK2 and JAK1 kinases, promising early safety data as well as “compelling activity” in relevant disease models. SDC-1801 has demonstrated excellent tolerability in toxicology studies in rodents and work is continuing towards completing the dose-finding and longer-term toxicology studies ahead of human trials.
GLALTH
Apologies, long post alert!
PART1:
As we know, Baricitinib is a JAK1/JAK2 inhibitor licensed to Lilly from Incyte and marketed as OLUMIANT. It is approved in more than 70 countries as a treatment for adults with moderately to severely active RA.
Lilly have been studying baricitinib in controlled trials in order to better characterize its potential benefits and understand the safety of its use as a COVID-19 treatment.
Eli Lilly and Incyte released initial data in a couple of weeks ago emerging from an Adaptive COVID-19 Treatment Trial sponsored by the National Institute of Allergy and Infectious Diseases. The study began in May and included more than 1,000 patients to assess the efficacy and safety of a 4-mg dose of baricitinib with remdesivir versus remdesivir in hospitalized patients with COVID-19.
Baricitinib in combination with remdesivir met the primary endpoint of reduction of time to recovery in comparison with remdesivir. There was an approximate one-day reduction in median recovery time for the overall patient population treated with baricitinib in combination with remdesivir versus those treated with remdesivir.
This finding is statistically significant. Recovery was defined as the participant being well enough for hospital discharge, meaning the participant either no longer required supplemental oxygen or ongoing medical care in the hospital, or was no longer hospitalized at Day 29. The study also met a key secondary endpoint comparing patient outcomes at Day 15 using an ordinal 8-point scale ranging from fully recovered to death.
Excellent news to wake up to!! We now have legal, sole rights across all of the main territories for our wholly owned main compound TYK2/JAK1.
Hopefully this is the start of the “end game” as real negotiations can now start.
GLALTH
Hi elcap,
First off, thanks for taking the time to email the Non-Exec Chairman and the Founder/CEO of SAR with questions that at on a lot of LTH’s minds .
Couple of questions, if you don’t mind:
1) who responded to you
2) was that one liner the entire content of the response?!
Thanks in advance,
SP
A few of us were discussing this report a while ago, but back then, there was no mention of expanding into the US.
See my previous post:
SRA 737 is available for licensing 18 Jun 2020 09:54
Hello all,
Apologies if this has already been posted. But Just seen this on AddisInsight, which for those who don’t know, is a database for drug research and development, disease treatment and decision making. It is based on trusted, scientifically sound data, which is reviewed, assessed and summarized by a team of expert scientists. They provide results on drugs, trials, deals, safety and patents.
Anyway, I stumbled across the SRA-737 profile:
https://adisinsight.springer.com/drugs/800045596
As you can see, it states:
04 Jun 2020
SRA 737 is available for licensing as of 04 Jun 2020. https://www.sierraoncology.com/
Was SRA-737 only put up in the shop window 2 weeks ago? On AddisInsight’s drug profile, they have linked to the SRRA site for onlicensing....but as we all know, this has now been taken down off.
Make of that what you will Sareumites!
GLA
MOMO who?!!!
Another bullish score given to SRRA yesterday:
https://www.investorsobserver.com/news/stock-update/sierra-oncology-inc-srra-stock-what-does-the-chart-say
interestingly, look who they have called out as SRRA’s “lead drug candidate” ...... Our very own SRA737
Yes hope so too Phil.
Yesterday, analysts were sending out bullish buy signals on SRRA:
https://oracledispatch.com/2020/08/19/the-rejuvenation-of-sierra-oncology-inc-nasdaqsrra/
Hopefully all will revealed soon...
London, X0, based Investment company Abingworth LLP sold out a holding in Sierra Oncology Inc yesterday.
The sale prices were between $8.88 and $15.31, with an estimated average price of $12.34.
The plot thickens with CHK1 (will we get our milestone, will it be on-licensed or will it be returned?)...
London, X0, based Investment company Abingworth LLP
Protein Kinase Serine / Threonine Chk1 Market Divided By Type:
CCT-244747, FS-105, GDC-0575
Protein Kinase Serine / Threonine Chk1 Market Split By Application:
Clinic, hospital
The Global Serine / Threonine Chk1 Protein Kinase Market report classified the information and data according to major geographic regions such as:
North America: United States, Canada and Mexico.
South and Central America: Argentina, Chile and Brazil.
The Middle East and Africa: Saudi Arabia, United Arab Emirates, Turkey, Egypt and South Africa.
Europe: United Kingdom, France, Italy, Germany, Spain and Russia.
Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore and Australia
The goals of the Chk1 Serine / Threonine Protein Kinase Market Study are:
Overview of Serine / Threonine Chk1 Protein Kinase Market Status and Future Forecast 2020 to 2029
Protein kinase serine / threonine Chk1 Market report discussed product developments, partnerships, mergers and acquisitions, R&D projects are mentioned
Serine / Threonine Chk1 Protein Kinase Market Details on Opportunities and Challenges, Restraints and Risks, Market Drivers, Challenges.
general competitive scenario, including the main market players, their growth targets, expansions, deals.
Detailed Description about Serine / Threonine Chk1 Protein Kinase Market manufacturers, sales, revenue, market share, and recent developments for key players.
To analyze and research the Serine / Threonine Chk1 Protein Kinase Market by regions, type, companies, and applications.
Why search Market.us Research ?:
Market.US specializes in in-depth market research and analysis and has proven its worth as a custom market research and consulting company as well as being a highly sought-after syndicated market research report provider. Market.US provides customization to suit any specific or unique requirement and tailor reports based on request. We go beyond the limits to take analytics, analysis, study and perspective to new heights and broader horizons. We offer tactical and strategic support, enabling our esteemed clients to make well-informed business decisions and chart future plans and achieve success every time. In addition to analysis and scenarios, we provide information and data on a global, regional and national level to ensure that nothing is hidden in any target market. Our team of tried and tested people continue to break down barriers in the market research arena as we move forward with a new and ever-expanding focus on emerging markets.
Came across this website offering a detailed report on Global Protein Kinase Serine / Threonine Chk1 Market Growth Drivers and Forecast Demand for the “Top Players” in 2020-2029 (Canbas Co Ltd, Cascadian Therapeutics Inc, Eli Lilly and Company, Genentech Inc, ProNAi Therapeutics Inc, SAREUM Holdings Plc).
https://teknlifenews.com/global-proteina-quinasa-serina-treonina-chk1-mercado-2020-2029/
Look the liberty of translating from Spanish:
The Chk1 Serine / Threonine Protein Kinase with a complete segmentation of key market manufacturers by geological regions, product type and end customer business applications. The Serine / Threonine Chk1 Protein Kinase Market Description, Applications, Production chain structure incorporating Serine / Threonine Chk1 Protein Kinase Market factors including drivers, restraints, SWOT examination, and risk analysis are presented. The Serine / Threonine Chk1 Protein Kinase Market Report presents data and information on the development of the investment structure, technological improvements, market trends and developments, capabilities, and comprehensive information on the key players of the Chk1 Serine / Threonine Protein Kinase Market. This report also focuses on key trends, growth drivers, dynamics, growth drivers, constraints, threats, challenges. The report also offers a comprehensive study of growth, market share, competitive landscape, sales analysis, new developments, and opportunity analysis.
Get a sample PDF copy of this report to understand the structure of the full report: (Includes full TOC, list of tables and figures, graph): https: //market.us/report/serine-threonine-protein-kinase- chk1-market / request-sample /
The qualitative data that is received is the result of several primary and secondary investigations. Exam analysts take the demand and size of the market and further validate themselves with the market experts. In addition, raw materials and instrumentation and demand analysis are managed downstream. The researchers focused on the new purposes of the market and implemented a comprehensive study of current market situations.
The report also offers a comprehensive study of key market dynamics and its latest trends, along with related market segments and sub-segments. The report looks at the major players from various regions and analysis at each industry level. Aggregate historical data from previous years on company profiles CanBas Co Ltd, Cascadian Therapeutics Inc, Eli Lilly and Company, Genentech Inc, ProNAi Therapeutics Inc, Sareum Holdings Plc, Sareum Holdings Plc Key in Serine Protein Kinase Market / threonine Chk1.
Several Serine / Threonine Chk1 Protein Kinase Market Segments Evaluated in the Report:
The top market manufacturers covered in the Serine / Threonine Chk1 Protein Kinase Market are:
CanBas Co Ltd
Cascadian Therapeutics Inc
Eli Lilly and Company
Genentech Inc
ProNAi Therapeutics Inc
Sareum Holdings Plc
SEE NEXT POST....